Table 1. Patients characteristics.
patient number | age | phenotype (months) | CNS Involvement | hyperleucytosis | Karyotype | FISH | Corticosensitivity | Chemosensitivity |
---|---|---|---|---|---|---|---|---|
1 | 154 | LAL T | no | yes | abnormal | tel-aml1 | yes | yes |
2 | 82 | LAL B | no | no | abnormal | negative | yes | yes |
3 | 114 | LAL B | no | no | abnormal | negative | yes | yes |
4 | 52 | LAL B | no | no | abnormal | negative | no | yes |
5 | 35 | LAL B | no | no | abnormal | negative | yes | yes |
6 | 53 | LAL B | no | no | abnormal | negative | not evaluable | yes |
7 | 107 | LAL B | no | no | abnormal | negative | yes | yes |
8 | 45 | LAL B | no | no | normal | negative | no | yes |
9 | 190 | LAL B | no | no | abnormal | tel-aml1 | yes | yes |
10 | 65 | LAL B | no | no | normal | negative | not | yes |
11 | 91 | LAL B | no | no | abnormal | negative | ye | yes |
12 | 196 | LAL B | no | no | normal | tel-aml1 | yes | yes |
13 | 35 | LAL B | no | no | abnormal | not done | no | yes |
14 | 180 | LAL T | no | no | Failure | negative | yes | yes |
15 | 76 | LAL B | no | no | normal | negative | yes | yes |
16 | 61 | LAL B | no | no | abnormal | negative | yes | yes |
17 | 183 | LAL B | no | no | abnormal | negative | yes | yes |
18 | 91 | LAL B | no | no | normal | negative | yes | yes |
19 | 38 | LAL B | no | yes | abnormal | negative | yes | yes |
20 | 50 | LAL B | no | yes | normal | negative | yes | yes |
21 | 195 | LAL B | no | no | normal | tel-aml1 | yes | yes |
22 | 78 | LAL B | no | no | abnormal | negative | not evaluable | yes |
23 | 23 | LAL B | no | no | abnormal | tel-aml1 | not evaluable | yes |
24 | 72 | LAL B | yes | no | normal | negative | yes | yes |
25 | 39 | LAL B | no | no | normal | negative | not evaluable | yes |
26 | 35 | LAL B | no | no | abnormal | tel-aml1 | no | yes |
27 | 57 | LAL B | no | no | abnormal | negative | yes | yes |
28 | 55 | LAL B | no | yes | normal | negative | not evaluable | yes |
29 | 149 | LAL T | no | no | normal | tel-aml1 | yes | yes |
30 | 28 | LAL B | no | no | normal | negative | yes | yes |
31 | 51 | LAL B | no | no | abnormal | negative | yes | yes |
32 | 23 | LAL B | no | no | abnormal | negative | yes | yes |
33 | 97 | LAL B | no | no | abnormal | tel-aml1 | not evaluable | yes |
34 | 75 | LAL B | no | no | normal | negative | yes | yes |
35 | 30 | LAL B | no | no | abnormal | mll+ | no | yes |
36 | 184 | LAL T | no | yes | normal | negative | not evaluable | yes |
37 | 107 | LAL B | no | no | normal | negative | yes | yes |
38 | 52 | LAL B | no | no | normal | tel-aml1 | no | yes |
39 | 43 | LAL B | no | yes | abnormal | negative | yes | yes |
40 | 158 | LAL B | no | no | normal | negative | yes | yes |
41 | 47 | LAL B | no | no | normal | negative | yes | yes |
42 | 58 | LAL B | no | no | abnormal | negative | yes | yes |
43 | 147 | LAL B | no | no | abnormal | negayive | yes | yes |
44 | 157 | LAL B | no | no | normal | negative | yes | yes |
45 | 145 | LAL B | no | no | normal | tel-aml1 | not evaluable | yes |
46 | 57 | LAL B | no | no | abnormal | negative | not evaluable | yes |
47 | 62 | LAL B | no | no | abnormal | negative | not evaluable | yes |